OptiNose, Inc.

Good day and thank you for standing by. Welcome to the OPTINO's fourth quarter 2022 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President of Investor Relations. Please go ahead.

Good morning, and thank you for joining us today as we review OptiNose's fourth quarter 2022 performance and our plans for the remainder of the year. I'm joined today by our chairman, Joe Scudari, our CEO, Dr. Rami Mahmoud, and our Chief Commercial Officer, Paul Spence. Joe is contributing to the prepared remarks portion of today's call. Rami, Paul, and I will host the question and answer session. The slides that will be presented on this call can be viewed on our website, optinose.com, in the investor section. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. All statements that are not historical facts are hereby identified as forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated by such statements. Additional information regarding these factors and forward-looking statements is discussed under the Cautionary Note on Forward-Looking Statements section of the earnings release that we issued today, as well as under the Risk Factors section and elsewhere in Opti-Nose's most recent Form 10-K and 10-Qs that are filed with the SEC and available on the website SEC.gov and on our website at Opti-Nose.com. Your caution not to place undue reliance on forward-looking statements The forward-looking statements during this conference call speak only as of the original date of this call or any earlier date indicated in such statement, and we undertake no obligation to update or revise any of these statements. We will now make prepared remarks, and then we will move to the question and answer session. With that, I will now turn the call over to Joe Scudari. Joe?

Thanks, Jonathan, and good morning, everyone. You've all had the opportunity to interact with Rami over the years in his prior position as President and Chief Operating Officer of the company. But given the recent decision to name him CEO, I'm taking this opportunity to introduce him and to share some perspectives about him on behalf of the board of directors. As you know, Peter recently made the decision to step down as CEO. In that context, the board confronted the question of CEO succession. Obviously, a very important decision for any company, private or public. As the board discussed this decision, we recognized that we were in this somewhat unique position for a company of our size to have a ready now candidate to promote into the position. As you know, Rami has been a part of building OptiNose from its very beginning and has been a very close working partner with Peter. The fact that he can step into the CEO position given that history is an incredible benefit to the company, its shareholders, the management team, all of our people, and the customers and patients we serve. I've known Rami for more than 20 years, dating from the time that we overlapped while we were both employed by Johnson & Johnson. In this case, while Rami served as a member of the management team at Janssen Pharmaceutica, and I served as company group chairman and later worldwide chairman of the pharmaceutical sector. During that period, in the very robust succession planning processes within J&J, Rami was consistently viewed as a rising star with significant upward potential for senior leadership roles, both within and beyond medical affairs and R&D. Over the past five years as chairman of the board for OptiNose, I've had the chance to work more closely with him and further recognize his leadership skills. We all recognize Rami's role in highlighting the development of a chance for chronic rhinosinusitis, but he brings much more to the senior leadership roles he has occupied and the board is confident he will do so as the company's CEO. It's rare to see a senior executive in our industry that is trained as an MD, served in the military, and combines a history of highly productive drug development with exceptional executive and leadership skills. Ramy's been an integral part of building OptiNose into what it is today. And notwithstanding the challenges the industry and the company has faced in the last few years, Ramy is ready now to lead the company into its next chapter of growth. With the filing of the supplemental NDA for the chronic rhinosinusitis indication now behind us, Rami will lead the effort to ensure the company is ready to launch its hands for this very important application. As you know, there is currently no FDA-approved therapy for this disease, and a high level of patient satisfaction with the therapeutic options currently available. The planning is already underway to get the company into the position to successfully launch X-Hands into a marketplace with significant unmet medical need in the not too distant future. I can speak on behalf of the entire board of directors when I say that we are thrilled that this executive transition has already occurred from the prior to the new CEO. We anticipate we will not miss a beat and that Rami will lead this team to the next level of success while maintaining the culture and values that have contributed to the company winning awards for being a great place to work. Thank you all for listening, and now I'll turn it over to Rami. Rami?